JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 15, 2003; DOI: 10.1124/jpet.103.051797


0022-3565/03/3063-954-964$20.00
JPET 306:954-964, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.051797v1
306/3/954    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millan, M. J.
Right arrow Articles by Cussac, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millan, M. J.
Right arrow Articles by Cussac, D.

NEUROPHARMACOLOGY

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

M. J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, J.-M. Rivet, and D. Cussac

Department of Psychopharmacology, Institut de Recherches Servier, Croissy/Seine, France

Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine (5-HT)2C receptors, respectively. It also interacted with h5-HT2B receptors (6.6), whereas it showed low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT receptors. In antibody capture/scintillation proximity assays, agomelatine concentration dependently and competitively abolished h5-HT2C receptor-mediated activation of Gq/11 and Gi3 (pA2 values of 6.0 and 6.1). As measured by [3H]phosphatidylinositol depletion, agomelatine abolished activation of phospholipase C by h5-HT2C (pKB value of 6.1) and h5-HT2B (pKB value of 6.6) receptors. In vivo, it dose dependently blocked induction of penile erections by the 5-HT2C agonists (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine (Ro60,0175) and 1-methyl-2-(5,8,8-trimethyl-8H-3-aza-cyclopenta[a]inden-3-yl) ethylamine (Ro60,0332). Furthermore, agomelatine dose dependently enhanced dialysis levels of dopamine in frontal cortex of freely moving rats, whereas they were unaffected in nucleus accumbens and striatum. Although the electrical activity of ventrotegmental dopaminergic neurons was unaffected agomelatine, it abolished their inhibition by Ro60,0175. Extracellular levels of noradrenaline in frontal cortex were also dose dependently enhanced by agomelatine in parallel with an acceleration in the firing rate of adrenergic cell bodies in the locus coeruleus. These increases in noradrenaline and dopamine levels were unaffected by the selective melatonin antagonist N-[2-(5-ethyl-benzo[b]thien-3-yl)ethyl] acetamide (S22153) and likely flect blockade of 5-HT2C receptors inhibitory to frontocortical dopaminergic and adrenergic pathways. Correspondingly, distinction to agomelatine, melatonin showed negligible activity 5-HT2C receptors and failed to modify the activity of adrenergic and dopaminergic pathways. In conclusion, in contrast to melatonin, agomelatine behaves as an antagonist at 5-HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.


Received March 18, 2003; accepted April 30, 2003.

Address correspondence to: Dr. Mark J. Millan, Institut de Recherches Servier, 125 chemin de Ronde 78290 Croissy/Seine, France. E-mail: mark.millan{at}fr.netgrs.com




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
C. R Dolder, M. Nelson, and M. Snider
Agomelatine Treatment of Major Depressive Disorder
Ann. Pharmacother., December 1, 2008; 42(12): 1822 - 1831.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
Y Le Strat and P Gorwood
Agomelatine, an innovative pharmacological response to unmet needs
J Psychopharmacol, September 1, 2008; 22(7_suppl): 4 - 8.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
G. Goodwin
Innovation translates into antidepressant effectiveness
J Psychopharmacol, September 1, 2008; 22(7_suppl): 9 - 12.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
R. Lam
Addressing circadian rhythm disturbances in depressed patients
J Psychopharmacol, September 1, 2008; 22(7_suppl): 13 - 18.
[Abstract] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
C. A. McClung
Role for the Clock Gene in Bipolar Disorder
Cold Spring Harb Symp Quant Biol, January 1, 2007; 72(0): 637 - 644.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.